Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies (Q83564738)
Jump to navigation
Jump to search
scientific article published on 08 March 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies |
scientific article published on 08 March 2011 |
Statements
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies (English)
W P Yong
B C Goh
R A Soo
H C Toh
K Ethirajulu
J Wood
V Novotny-Diermayr
S C Lee
W L Yeo
D Chan
D Lim
E Seah
R Lim